Cathie's Ark Logo
Beam Therapeutics Inc Logo

ARKK Holdings of Beam Therapeutics (BEAM) - Updated Daily

TherapeuticsGene TherapyGenomicsGene Base Editing
Date
Direction
Shares
Fund Weight
Fund
May 8, 2023
BUY3.236k0.0015%ARKK
May 2, 2023
BUY22.679k0.0102%ARKK
May 1, 2023
BUY3.350k0.0015%ARKK
April 28, 2023
BUY2.523k0.0011%ARKK
April 27, 2023
BUY25.831k0.0119%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
2.61%$2.48b
🏋🏿‍♂️Weight Rank In ARKK🌏Country
16🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
18$80.30
🎫ARK Ownership Percent
8.22%
Description
beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team:  a community of fearless innovators  rigorous and honest in our research  listening with open minds  committed to each other
Website
beamtx.com

Other ETFs That Hold BEAM

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.87%
GNOMGlobal X Genomics & Biotechnology ETF3.11%
ARKKARK Innovation ETF2.92%
XBISPDR® S&P Biotech ETF0.94%
IBBiShares Biotechnology ETF0.22%
LABUS&P Biotech Bull 3X Shares ETF0.204%

Research Notes and Commentary for BEAM

No Research Notes Found for BEAM